Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
3356 participants
INTERVENTIONAL
2024-11-01
2029-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To identify chronic kidney disease in First Nations adults in Manitoba
* To risk stratify patients as low, moderate and high risk of kidney failure and organize active surveillance by risk category
* To initiate treatments to prevent to progression of chronic kidney disease in individuals at risk of kidney failure
Participants will be randomized to:
1. Patient contact via mail with a letter and laboratory requisition for serum creatinine and urine Albumin Creatinine Ratio
2. Patient and primary care network contact via mail with a letter but no laboratory requisition
The primary outcome is the difference between groups in the proportion of individuals who undergo screening for chronic kidney disease within 6 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Kidney Check: Diabetes, Blood Pressure & Kidney Health Checks & Care in Indigenous Communities.
NCT03595267
Integrating Risk-based Care for Patients With CKD
NCT03365063
Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease
NCT06750575
Effect of Exercise on Renal Function in Predialysis
NCT02155036
Chronic Kidney Disease Clinical Decision Support
NCT03890588
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient contact via mail with a letter and laboratory requisition
Patient contact via mail with a letter and laboratory requisition for serum creatinine and urine albumin to creatinine ratio
population-based screening for chronic kidney disease
Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
Patient and primary care network contact via mail with a letter but no laboratory requisition
population-based screening for chronic kidney disease
Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
population-based screening for chronic kidney disease
Randomized controlled trial that uses an integrated health platform for eligibility and outcome assessments
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Resident of Manitoba
* First Nations
* Urban, rural or remote location
Exclusion Criteria
* chronic kidney disease (estimated Glomerular Filtration Rate \<60 milliliter/1.73square meter for 3 months)
* Screening for chronic kidney disease with estimated Glomerular Filtration Rate or Albumin to Creatinine ratio in the last 2 years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Research Manitoba
OTHER
Manitoba Health, Seniors and Long-Term Care, Province of Manitoba
UNKNOWN
First Nations Health and Social Secretariat of Manitoba
UNKNOWN
Shared Health Manitoba
UNKNOWN
Seven Oaks General Hospital
UNKNOWN
University of Manitoba
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Collister, MD, PhD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
University of Manitoba
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chronic Disease Innovation Centre
Winnipeg, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HS24845 (H2021:170)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.